Mycophenolic acid interactions

Food & lifestyle

• high-fat foods

  Moderate

  Absorption

  Administration of enteric coated mycophenolic acid with meals may alter its pharmacokinetics relative to administration in the fasting state. When mycophenolic acid 720 mg was administered with a high-fat meal, there was a 33% decrease in the peak plasma concentration (Cmax); a 3.5-hour increase in delay time for the rise of plasma mycophenolic acid; and a 5-hour delay in the time to reach peak plasma concentration (Tmax). However, no effect was observed on the systemic exposure of mycophenolic acid.

  What to do: To avoid variability in drug absorption between doses, enteric coated formulations of mycophenolic acid should be taken on an empty stomach, one hour before or two hours after food intake. The tablets should be swallowed whole and not crushed, chewed or divided in order to maintain the integrity of the enteric coating.

  1 source

  1. "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals (2004):

Conditions

Conditions in which Mycophenolic acid needs care, as documented in this source.

• Infections

  Major

  Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

  10 sources

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  3. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  4. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  5. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  6. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  7. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
  8. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):

  Show all 10 sourcesShow fewer sources

  9. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
  10. "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals (2021):

• Lesch-Nyhan Syndrome

  Major

  The use of mycophenolic acid should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms.

  1 source

  1. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):

• Leukoencephalopathy, Progressive Multifocal

  Major

  Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.

  8 sources

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc (2004):
  3. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  4. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  5. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  6. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  7. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  8. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):

• Gastrointestinal Diseases

  Moderate

  The use of mycophenolic acid may cause gastrointestinal bleeding (requiring hospitalization), intestinal perforations, gastric ulcers, and duodenal ulcers. Mycophenolic acid should be administered with caution in patients with active serious digestive system disease.

  1 source

  1. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):

• Skin Neoplasms

  Moderate

  The use of mycophenolic acid increases the risk of developing lymphomas and other malignancies, particularly of the skin. Patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Care should be exercised when using mycophenolic acid in patients with these conditions.

  1 source

  1. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):